Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Jose R. Conejo-Garcia"'
Autor:
Gary K. Koski, Amrita Basu, Payal Grover, Qianxing Mo, Hatem Soliman, Brian J. Czerniecki, Hyo S. Han, Mark I. Greene, Doris Wiener, Colin Snyder, Hongtao Zhang, Yong-Zi Chen, Jose R. Conejo-Garcia, Ricardo Costa, Ganesan Ramamoorthi, Zhongsheng Tong, Krithika Kodumudi, Catherine A. Lee, Shari Pilon-Thomas, Yongsheng Jia
Publikováno v:
Molecular Therapy. 29:1541-1556
HER2 breast cancer (BC) remains a significant problem in patients with locally advanced or metastatic BC. We investigated the relationship between T helper 1 (Th1) immune response and the proteasomal degradation pathway (PDP), in HER2-sensitive and -
Autor:
Haiyan Bai, Alvaro S Padron, Yilun Deng, Yiji J Liao, Clare J Murray, Carlos Ontiveros, Suresh J Kari, Aravind Kancharla, Anand V R Kornepati, Myrna Garcia, Ryan Michael Reyes, Harshita B Gupta, Jose R Conejo-Garcia, Tyler Curiel
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e004871
BackgroundTumor intracellular programmed cell death ligand-1 (PDL1) mediates pathologic signals that regulate clinical treatment responses distinctly from surface-expressed PDL1 targeted by αPDL1 immune checkpoint blockade antibodies.MethodsWe perfo
Autor:
Ahmad A Tarhini, Sandra J Lee, Aik-Choon Tan, Issam M El Naqa, F Stephen Hodi, Lisa H Butterfield, William A LaFramboise, Walter J Storkus, Arivarasan D Karunamurthy, Jose R Conejo-Garcia, Patrick Hwu, Howard Streicher, Vernon K Sondak, John M Kirkwood
Publikováno v:
Journal for immunotherapy of cancer, vol 10, iss 1
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
BackgroundMelanoma of unknown primary (MUP) represents a poorly understood group of patients both clinically and immunologically. We investigated differences in prognosis and candidate immune biomarkers in patients with unknown compared with those wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6594a7e70e14c1deed6cba96d4698ce
https://escholarship.org/uc/item/4dh8b1ng
https://escholarship.org/uc/item/4dh8b1ng
Autor:
Rachel C. Newsome, Raad Z. Gharaibeh, Christine M. Pierce, Wildson Vieira da Silva, Shirlene Paul, Stephanie R. Hogue, Qin Yu, Scott Antonia, Jose R. Conejo-Garcia, Lary A. Robinson, Christian Jobin
Publikováno v:
Genome medicine. 14(1)
BackgroundRecent studies show that human gut microbial composition can determine whether a patient is a responder or non-responder to immunotherapy but have not identified a common microbial signal shared by responding patients. The functional relati
Autor:
Xuefeng Wang, Jameel Muzaffar, Kedar Kirtane, Feifei Song, Matthew Johnson, Michael J Schell, Jiannong Li, Sean J Yoder, Jose R Conejo-Garcia, Jose A Guevara-Patino, Marcelo Bonomi, Priyanka Bhateja, James W Rocco, Conor E Steuer, Nabil F Saba, Christine H Chung
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004512
BackgroundT cell receptor (TCR) signaling profile is a fundamental property that underpins both adaptive and innate immunity in the host. Despite its potential clinical relevance, the TCR repertoire in peripheral blood has not been thoroughly explore
Autor:
Alycia Gardner, Álvaro de Mingo Pulido, Kay Hänggi, Sarah Bazargan, Alexis Onimus, Agnieszka Kasprzak, Jose R Conejo-Garcia, Katarzyna A Rejniak, Brian Ruffell
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e003571
BackgroundT cell immunoglobulin and mucin domain containing−3 (TIM-3) blocking antibodies are currently being evaluated in clinical trials for solid and hematological malignancies. Despite its identification on T cells, TIM-3 is predominantly expre
Autor:
Lisa H. Butterfield, Ahmad A. Tarhini, Howard Streicher, F. Stephen Hodi, Sandra J. Lee, Issam El Naqa, Vernon K. Sondak, John M. Kirkwood, Mariam Saad, Patrick Hwu, Walter J. Storkus, Jose R. Conejo-Garcia, Aik Choon Tan, William A. LaFramboise
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundSex differences in tumor immunity and response to immunotherapy were shown in murine models and descriptive analyses from recent clinical trials. We recently reported that female gender is a favorable prognostic marker for survival benefit
Autor:
John M. Kirkwood, Ahmad A. Tarhini, Aik Choon Tan, F. Stephen Hodi, William A. LaFramboise, Patrick Hwu, Howard Streicher, Walter J. Storkus, Jose R. Conejo-Garcia, Sandra J. Lee, Issam El Naqa, Vernon K. Sondak, Lisa H. Butterfield
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundWe recently reported data supporting the unknown primary status as a potentially distinct prognostic group among high-risk melanoma patients treated with ipilimumab and high dose interferon-alfa (HDI) in the ECOG-ACRIN E1609 trial (N=1670)
Autor:
Ryan Reyes, Chenghao Zhang, Karen Wheeler, Alvaro Padron, Neelam Mukherjee, Deyi Zhang, Harshita Gupta, Aravind Kancharla, Jose R. Conejo-Garcia, Anand Kornepati, Niannian Ji, Myrna Garcia, Robert S. Svatek, Tyler J. Curiel, Yilun Deng, Onur Boyman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundAnti-programmed death-ligand 1 (αPD-L1) immunotherapy is approved to treat bladder cancer (BC) but is effective in + antitumor T cells known to improve αPD-L1 efficacy. We hypothesized that the tumor microenvironment, including local immu
Autor:
Shadmehr Demehri, Adekunle Odunsi, Kathryn Kadash-Edmondson, Eliezer M. Van Allen, Claire McCarthy, Zachary S. Morris, Conrad Russell Y. Cruz, Song Liu, Steven M. Lipkin, Andrew G. Sikora, Lawrence Fong, Eduardo Vilar, Wenjuan Zha, Michael A. Demetriou, Ananth Annapragada, Marcelo C. Pasquini, Martin Morgan, Levon Demirdjian, Stephen Schoenberger, Catherine M. Bollard, Jose R. Conejo-Garcia, Yi Xing, Donald Kufe, Alan D. Hutson, Yang Pan, Mary M. Horowitz
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Despite regulatory approval of several immune-based treatments for cancer in the past decade, a number of barriers remain to be addressed in order to fully harness the therapeutic potential of the immune system and provide benefits for patients with